Anti-seizure drug shows promise against aggressive childhood brain tumors in Stanford study
Source Summary
Stanford Medicine researchers found that an existing anti-seizure drug slows the growth of diffuse midline gliomas, a devastating group of childhood cancers affecting the brain and spinal cord. These tumors strike 300 to 400 U.S. children annually and have a five-year survival rate of approximately 1%.
Why it matters
A drug that slows growth of tumors with a 1% five-year survival rate represents a potential therapeutic advance for a rare but uniformly fatal childhood cancer.
